PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10944865

Recombinant tissue plasminogen activator for central venous access device occlusion.

C Hooke
View original source ↗Export metadata ↓

Abstract

Maintaining and restoring the function of central venous access devices (CVAD) is an important component of pediatric oncology nursing care. Until 1999, Abbokinase Open Cath (urokinase; Abbott, Abbott Park, IL), a thrombolytic agent was the product primarily used to resolve thrombotic occlusions in intravascular devices. Changes in the manufacturing process mandated by the FDA have resulted in a lack of availability of Abbokinase Open Cath. Recombinant tissue plasminogen activator (TPA) has provided an alternative solution for clearing occluded intravascular devices. This article reviews the literature supporting the use of TPA for CVAD clearance and discusses the process of how to administer the medication. Future implications for research about the use of TPA, and its role in the care of CVADs are discussed.

Explore related subjects

Catheterization, Central VenousEquipment FailureFibrinolytic AgentsHumansOncology NursingPediatric NursingThrombosisTissue Plasminogen ActivatorJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Hooke. 2000. Recombinant tissue plasminogen activator for central venous access device occlusion.. https://doi.org/10.1053/jpon.2000.8065

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A novel technique in selective venous sampling in the localization of parathyroid tumours utilizing a micro-wire and standardized catheter.

Selective venous sampling (SVS) is a useful technique to localize a number of hormone-producing tumours, such as parathyroid tumours, when other imaging techniques are inconclusive. Typically, a 5 French selective single end-hole catheter and standard hydrophilic wire are utilized to access the required vessels and an attempt made to withdraw blood. However, most interventional radiologists are familiar with the difficulty and limited success in withdrawing venous blood through an end-hole catheter. We describe a simple, cheap and novel technique utilizing a micro-wire that we have developed in our interventional suite to overcome this common problem. Having reached the target site with the selective end-hole catheter, a Tuohy Borst adapter is attached to the catheter end. A 0.018-inch micro-wire is then inserted through the selective end-hole catheter such that the distal wire tip exits the distal catheter tip. The purpose of the micro-wire exiting the catheter is to both straighten the catheter tip to a position parallel to the vessel, allowing easier aspiration as well as physically preventing blockage of the catheter by the vein intimal wall collapse on suction. The 5-ml sample required for PTH assay is then successfully obtained via the Tuohy Borst adapter.

Catheterization, Central Venous↗
PubMed2007

[Subclavian thrombosis after port system implantation].

The use of implanted central venous catheters with ports has become almost irreplaceable in clinical treatment of cancer patients with advanced disease. It improves the patient's quality of life and simplifies medical treatment. For safe use during outpatient follow-up treatment, possible complications such as wound infections, thrombosis or even pulmonary embolism have to be considered. The incidence of catheter-associated thrombosis in cancer patients has been estimated as 25-66% in screening evaluations. Clinical symptoms were present in only in 6-28% of all patients with diagnosed thromboses. We report on a patient with metastatic malignant melanoma, who developed a deep arm vein thrombosis two weeks after port implantation. The prognosis of deep arm vein thrombosis is determined by the development of pulmonary embolism (8-36%). In such cases, early diagnosis and treatment are essential for the patient's survival.

Catheterization, Central Venous↗